Last reviewed · How we verify

ZN-c3 — Competitive Intelligence Brief

ZN-c3 (zn-c3) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ZN-c3 tablet by mouth, in combination with encorafenib. Area: Oncology.

discontinued ZN-c3 tablet by mouth, in combination with encorafenib Oncology Live · refreshed every 30 min

Target snapshot

ZN-c3 (zn-c3) — Pfizer Inc.. ZN-c3 tablet by mouth, in combination with encorafenib

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ZN-c3 TARGET zn-c3 Pfizer Inc. discontinued ZN-c3 tablet by mouth, in combination with encorafenib

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ZN-c3 tablet by mouth, in combination with encorafenib class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ZN-c3 — Competitive Intelligence Brief. https://druglandscape.com/ci/zn-c3. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: